CARMAT, a developer of artificial hearts, surpasses its funding goal by EUR40.5 million
CARMAT has raised EUR40.5m in funding. The money raised will be used to fund the production of the Aeson artificial hearts, which are hoped to provide an alternative treatment for heart failure patients – around 6.2 millions adults suffer from this condition in the US.
Longevity. Your heart beats around 100,000 times a day to keep you healthy. Your heartbeat will be a constant source of comfort throughout your entire life. The heart is the central organ of the circulatory systems, constantly pumping blood to the cells to provide oxygen and nutrients. Unfortunately, due to the constant work of our hearts, they can wear out with age. Cardiovascular diseases are still the leading cause of death worldwide [2].
The condition of end-stage heart failure occurs when the heart is no longer able to transport blood effectively throughout the body. Biventricular heart failure is most common when it affects the left heart chamber, which pumps oxygenated blood throughout the body. The brain, kidney and liver do not receive enough oxygen or nutrients to function correctly. End-stage heart failure is often treated with serious interventions like heart transplantation, which is considered to be the gold standard. Due to the global shortage of organ donors, however, this isn’t always possible. There is a need for an alternative therapeutic option that could have a huge impact on longevity worldwide.
Source:
Artificial heart developer CARMAT beats €40.5 million funding goal
